A growing understanding of the multiple genetic and environmental pathways that contribute to the development of cancer is leading to the concept of a personalized approach to cancer therapy and prevention. This requires techniques to characterize patient and tumor factors that will drive specific targeted interventions and measure their effectiveness. Biomedical imaging now offers the opportunity to characterize tumor anatomy, physiology, and molecular biology in unprecedented ways. The challenge is to harness this technology to develop quantitative approaches to diagnosis that will support the development and application of targeted treatments and preventive interventions. Since its inception, ACRIN has developed and implemented multicenter clinical trials to establish the effectiveness of imaging in the detection, characterization and monitoring of cancer. Working with its biostatistics center at Brown University, ACRIN has assembled a unique organization of hundreds of clinical imaging specialists, other clinicians, and non-physician researchers at more than a hundred institutions nationally and internationally working collaboratively with the broader cancer research community dedicated to cancer imaging research. Over the next grant cycle, ACRIN proposes 3 major scientific objective related to the theme of personalized cancer care: 1. targeted surveillance of at-risk populations;2.characterization of cancer in order to drive targeted therapy;and 3. development of imaging-based predictive and prognostic biomarkers of response to targeted treatment. Through its continued leadership in the imaging community, ACRIN will play a pivotal role in the advancement of cancer detection and therapy. ACRIN will work to discover ways for imaging to improve cancer care. This includes determining the optimal methods to detect cancer early in order to provide the best opportunity for cure, and establishing techniques to characterize cancer and its response to treatment in order to choose the most appropriate therapy.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Cooperative Clinical Research--Cooperative Agreements (U10)
Project #
3U10CA080098-14S2
Application #
8528753
Study Section
Special Emphasis Panel (ZCA1-SRRB-9 (O1))
Program Officer
Henderson, Lori A
Project Start
1999-03-06
Project End
2014-12-31
Budget Start
2013-01-01
Budget End
2014-12-31
Support Year
14
Fiscal Year
2013
Total Cost
$5,146,722
Indirect Cost
$1,226,114
Name
American College of Radiology
Department
Type
DUNS #
062485800
City
Reston
State
VA
Country
United States
Zip Code
20191
Hylton, Nola M; Gatsonis, Constantine A; Rosen, Mark A et al. (2016) Neoadjuvant Chemotherapy for Breast Cancer: Functional Tumor Volume by MR Imaging Predicts Recurrence-free Survival-Results from the ACRIN 6657/CALGB 150007 I-SPY 1 TRIAL. Radiology 279:44-55
Atri, Mostafa; Zhang, Zheng; Dehdashti, Farrokh et al. (2016) Utility of PET-CT to evaluate retroperitoneal lymph node metastasis in advanced cervical cancer: Results of ACRIN6671/GOG0233 trial. Gynecol Oncol 142:413-9
Markovina, Stephanie; Duan, Fenghai; Snyder, Bradley S et al. (2015) Regional Lymph Node Uptake of [(18)F]Fluorodeoxyglucose After Definitive Chemoradiation Therapy Predicts Local-Regional Failure of Locally Advanced Non-Small Cell Lung Cancer: Results of ACRIN 6668/RTOG 0235. Int J Radiat Oncol Biol Phys 93:597-605
Magbanua, Mark Jesus M; Wolf, Denise M; Yau, Christina et al. (2015) Serial expression analysis of breast tumors during neoadjuvant chemotherapy reveals changes in cell cycle and immune pathways associated with recurrence and response. Breast Cancer Res 17:73
Newitt, David C; Tan, Ek T; Wilmes, Lisa J et al. (2015) Gradient nonlinearity correction to improve apparent diffusion coefficient accuracy and standardization in the american college of radiology imaging network 6698 breast cancer trial. J Magn Reson Imaging 42:908-19
Park, Elyse R; Gareen, Ilana F; Japuntich, Sandra et al. (2015) Primary Care Provider-Delivered Smoking Cessation Interventions and Smoking Cessation Among Participants in the National Lung Screening Trial. JAMA Intern Med 175:1509-16
Atri, Mostafa; Zhang, Zheng; Marques, Helga et al. (2015) Utility of preoperative ferumoxtran-10 MRI to evaluate retroperitoneal lymph node metastasis in advanced cervical cancer: Results of ACRIN 6671/GOG 0233. Eur J Radiol Open 2:11-18
Black, William C (2015) Computed tomography screening for lung cancer in the National Lung Screening Trial: a cost-effectiveness analysis. J Thorac Imaging 30:79-87
Cureton, Elizabeth L; Yau, Christina; Alvarado, Michael D et al. (2014) Local recurrence rates are low in high-risk neoadjuvant breast cancer in the I-SPY 1 Trial (CALGB 150007/150012; ACRIN 6657). Ann Surg Oncol 21:2889-96
Mukhtar, Rita A; Yau, Christina; Rosen, Mark et al. (2013) Clinically meaningful tumor reduction rates vary by prechemotherapy MRI phenotype and tumor subtype in the I-SPY 1 TRIAL (CALGB 150007/150012; ACRIN 6657). Ann Surg Oncol 20:3823-30

Showing the most recent 10 out of 26 publications